Axitinib
- PDF / 170,098 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 0 Downloads / 147 Views
1 S
Left ventricular dysfunction: case report A man in his 70s developed left ventricular dysfunction following treatment with axitinib for advanced renal cell carcinoma. The man presented to the hospital due to flank pain and radical nephrectomy showed renal cell carcinoma grade II. Later, he had recurrence along with pulmonary nodular lesions after 1.5 years. Hence, he received interferon alpha-2b. But, a CT scan demonstrated progression of the disease after 3 months. Therefore, second-line therapy with sunitinib was initiated. However, he developed grade III unspecified toxicities that required dose modification. His disease was stable on sunitinib for 18 months. However, he had progression of the disease. His further investigation showed metastatic renal cell carcinoma. Thus, third line treatment with axitinib 10 mg/day [route not stated] was commenced. Subsequently, he developed dyspnoea and palpitations in February 2018. His echocardiography showed ejection fraction of 35% and left ventricular dysfunction [duration of treatment to reaction onset not stated] was considered. The man was treated with diuretics, low molecular weight heparin and aspirin [acetylsalicylic acid]. Upon further investigation, it was considered that left ventricular dysfunction was secondary to axitinib and he scored 5 on the Naranjo Algorithm indicative of possible relationship between axitinib and cardiotoxicity. his treatment was continued. Additionally, metoprolol and Ramipril were started. Thereafter, a close follow-up was performed and he started receiving nivolumab. His initial ejection fraction was 32%. During the nivolumab therapy, he was closely monitored in the hospital. Eventually, he had improvement in his symptoms. After 3 months therapy, he had no symptoms of cardiac dysfunction and his ejection fraction was found to be 50%. At the follow-up visit in July 2019, his ejection fraction was found to be 52% with stable disease. Tanriverdi O, et al. Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma. Journal of Oncology Pharmacy 803518640 Practice 26: 1765-1768, No. 7, Oct 2020. Available from: URL: http://doi.org/10.1177/1078155220909422
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
